Case Report: Good cardiac tolerance to Toripalimab in a CVD patient with oral melanoma
Conclusions: This case provided evidence of Toripalimab combined with chemotherapy on melanoma patients with complex cardiovascular diseases. Toripalimab demonstrated a manageable safety profile and durable clinical response. In addition, the standard CHF treatment plays a vital role in the protection of cardiac function. In a cancer patient with complex cardiovascular diseases, standard prophylactic CHF treatment should be applied at an early stage.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Bisoprolol | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | China Health | Diovan | Drugs & Pharmacology | Genetics | Heart | Immunotherapy | Melanoma | Oral Cancer | Skin Cancer | Spironolactone | Toxicology